Effect of monoclonal antibodies to respiratory syncytial virus in preterm children with bronchopulmonary dysplasia according to follow-up
- Authors: Volyanyuk EV1,2, Safina AI2, Potapova MV1
-
Affiliations:
- Children’s Municipal Hospital №1, Kazan, Russia
- Kazan State Medical Academy, Kazan, Russia
- Issue: Vol 96, No 4 (2015)
- Pages: 505-509
- Section: Theoretical and clinical medicine
- URL: https://kazanmedjournal.ru/kazanmedj/article/view/2239
- DOI: https://doi.org/10.17750/KMJ2015-505
- ID: 2239
Cite item
Full Text
Abstract
Aim. To assess the effect and safety of palivizumab to prevent the bronchopulmonary dysplasia complications in preterm children according to follow-up.
Methods. The study included 48 very preterm infants (birth weight ranged from 732-1640 g) with bronchopulmonary dysplasia, who were divided into two groups. The main group included children who received passive immunization by palivizumab (31 children), the comparison group included un-immunized children (17 patients). The diagnosis of bronchopulmonary dysplasia in children at 28 days of postnatal life has been set according to clinical and radiological data. After being discharged from the department of pathology of newborn, children were followed-up for 12 months in the center of preterm children follow-up. Average age of patients with bronchopulmonary dysplasia was 4.2±1.3 months at passive immunization initiation. The drug was administered by intramuscular injection at a dose of 15 mg/kg once monthly.
Results. Lower respiratory tract infections were observed in 6 (19.3%) patients from the first group, including 4 cases of obstructive bronchitis and 2 cases of pneumonia. These patients received incomplete course of immunization. In children who did not receive specific prophylaxis, respiratory infections were registered in 7 (41.2%) patients, with 2 cases accompanied by severe respiratory failure requiring mechanical ventilation. No adverse effects were identified while palivizumab treatment.
Conclusion. Palivizumab is currently the only effective drug to prevent the severe respiratory syncytial virus infection; good safety of the drug makes it possible to reconsider the contraindication of its use in high-risk children with severe bronchopulmonary dysplasia.
Keywords
About the authors
E V Volyanyuk
Children’s Municipal Hospital №1, Kazan, Russia; Kazan State Medical Academy, Kazan, Russia
Author for correspondence.
Email: Evolanuk@mail.ru
A I Safina
Kazan State Medical Academy, Kazan, Russia
Email: Evolanuk@mail.ru
M V Potapova
Children’s Municipal Hospital №1, Kazan, Russia
Email: Evolanuk@mail.ru
References
- Бронхолёгочная дисплазия у детей / Методические рекомендации РАСПМ (научно-практическая программа). - Москва, 2012. - 58 с.
- Давыдова И.В., Намазова-Баранова Л.Т., Алтунин В.В. и др. Функциональная оценка респираторных нарушений у детей с бронхолёгочной дисплазией при катамнестическом наблюдении // Педиатр. фармакол. - 2014. - Т. 11, №6. - С. 42-52.
- Давыдова И.В., Яцык Г.В., Тресорукова О.В. и др. Клинико-функциональные особенности течения бронхолёгочной дисплазии в первом полугодии жизни // Рос. педиатр. ж. - 2008. - №6. - С. 10-12.
- Намазова-Баранова Л.Т., Давыдова И.В., Трути Т.В. и др. Современные возможности иммунопрофилактики тяжёлого течения респираторно-синцитиальной вирусной инфекции у детей с последствиями перинатальной патологии // Педиатр. фармакол. - 2011. - Т. 8, №4. - С. 92-100.
- Овсянников Д.Ю. Система оказания медицинской помощи детям, страдающим бронхолёгочной дисплазией. Руководство для практикующих врачей / Под ред. Л.Г. Кузьменко. - М.: МДВ, 2010. - 152 c.
- Петрова Н.А., Добродеева И.В., Пальчик А.Б., Шабалов Н.П. Апноэ и периодическое дыхание у новорождённых с бронхолёгочной дисплазией // Педиатрия. Ж. им. Г.Н. Сперанского. - 2009. - Т. 88, №1. - С. 13-18.
- American Thoracic Society Document. Statement Document. Statement on the care of the child with chronic lung disease of infancy and childhood // Am. J. Respir. Crit. Care Med. - 2003. - Vol. 168. - P. 365. http://dx.doi.org/10.1164/rccm.168.3.356
- Baraldi E., Filippone M. Chronic lung disease after premature birth // N. Engl. J. Med. - 2007. - Vol. 357. - Р. 1946-1955. http://dx.doi.org/10.1056/NEJMc073362
- Subramanian K.N., Weisman L.E., Rhodes T. et al. Safety, tolerance and pharmacokinetics of a humanized monoclonal antibody to respiratory syncytial virus in premature infants and infants with bronchopulmonary dysplasia // Pediatr. Infect. Dis. J. - 1998. - Vol. 17. - P. 110-115.
- Yu V.Y.H., Orgill A.A., Lim S.B. et al. Growth and development to very low birth weight in infants recovering from bronchopulmonary dysplasia // Arch. Dis. Childhood. - 1983. - Vol. 58 - С. 791-794.